Incidensen af alvorlige infektioner var 0, 04 pr. patientår hos Humira- behandlede patienter og 0, 03 pr. patientår hos placebo - og aktiv kontrolbehandlede patienter.
The incidence of serious infections was 0.04 per patient year in Humira treated patients and 0.03 per patient year in placebo and active control − treated patients.